Outlook Therapeutics

OTLK56

High Growth

$6.000.00%$0.00

High Growth

OTLK56

$6.00

0.00%$0.00

High Growth

Performance History

Key Stats
Open	$6.00
Prev. Close	$6.00
EPS	-5.89
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$141.93M
PE Ratio	-

	LOW	HIGH
Day Range	5.87	6.15
52 Week Range	4.10	18.00

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-5.89

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Outlook Therapeutics (OTLK)

Outlook Therapeutics Inc, commonly known as OTLK, is a biotechnology company that specializes in the development of innovative therapies for various eye diseases. The company focuses on creating solutions to address the unmet needs of patients suffering from retinal diseases, including diabetic retinopathy and wet age-related macular degeneration (wet AMD). OTLK's mission is to provide life-changing treatments that enhance the quality of life for patients around the world.

As of the latest financial data, Outlook Therapeutics Inc has a market capitalization of approximately $150 million. This value represents the total market value of the company's outstanding shares of stock. OTLK's stock price history has shown some volatility, as is common in the biotechnology sector. Investors should carefully monitor the market trends and news related to the company before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. C. Russell Trenary III
Headquarters: Iselin
Employees: 17
Exchange: NASDAQ

Keep an eye on Outlook Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Outlook Therapeutics 's (OTLK) price per share?

The current price per share for Outlook Therapeutics (OTLK) is $6. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Outlook Therapeutics (OTLK)?

For Outlook Therapeutics (OTLK), the 52-week high is $18, which is 200% from the current price. The 52-week low is $4.1, the current price is 46.34% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Outlook Therapeutics (OTLK) a growth stock?

Outlook Therapeutics (OTLK) has shown an average price growth of 0.41% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Outlook Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Outlook Therapeutics (OTLK) stock price performance year to date (YTD)?

As of the latest data, Outlook Therapeutics (OTLK) has a year-to-date price change of -23.68%. Over the past month, the stock has experienced a price change of -17.47%. Over the last three months, the change has been -21.36%. Over the past six months, the figure is -14.77%. Looking at a longer horizon, the five-year price change stands at -82.14%.

help

Is Outlook Therapeutics (OTLK) a profitable company?

Outlook Therapeutics (OTLK) has a net income of -$58.98M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$53.13M. Furthermore, the EBITDA is -$61.19M.

help

What is the market capitalization of Outlook Therapeutics (OTLK)?

Outlook Therapeutics (OTLK) has a market capitalization of $141.93M. The average daily trading volume is 405.57K, indicating the stock's liquidity and investor engagement.

News

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

CALENDAR OF EVENTS

CONFERENCE CALLS/ WEBCASTS

6/11/2024

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

HEALTH

5/28/2024

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

HEALTH

CLINICAL STUDY

5/13/2024

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

CONFERENCE CALLS/ WEBCASTS

5/9/2024

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast